NCT01449266View on ClinicalTrials.gov

Safety and Dialysability of Dotarem® in Dialysed Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

June 30, 2012

Conditions
End-stage Renal Failure
Interventions
DRUG

Dotarem® IV injection at 0.1 mmol/kg

Dotarem® was IV administered at a dose of 0.1 mmoL/kg (0.2 mL/kg).

Trial Locations (1)

Unknown

Clinical Pharmacology Unit Antwerp, Antwerp

Sponsors

Lead Sponsor

Guerbet
All Listed Sponsors
lead

Guerbet

INDUSTRY